Literature DB >> 33569054

RGC-32 Regulates Generation of Reactive Astrocytes in Experimental Autoimmune Encephalomyelitis.

Alexandru Tatomir1,2, Austin Beltrand1, Vinh Nguyen3, Dallas Boodhoo1, Armugam Mekala1, Cornelia Cudrici4, Tudor C Badea5, Dafin F Muresanu2, Violeta Rus3, Horea Rus1,6.   

Abstract

Astrocytes are increasingly recognized as critical contributors to multiple sclerosis pathogenesis. We have previously shown that lack of Response Gene to Complement 32 (RGC-32) alters astrocyte morphology in the spinal cord at the peak of experimental autoimmune encephalomyelitis (EAE), suggesting a role for RGC-32 in astrocyte differentiation. In this study, we analyzed the expression and distribution of astrocytes and astrocyte progenitors by immunohistochemistry in spinal cords of wild-type (WT) and RGC-32-knockout (KO) mice with EAE and of normal adult mice. Our analysis showed that during acute EAE, WT astrocytes had a reactive morphology and increased GFAP expression, whereas RGC-32 KO astrocytes had a morphology similar to that of radial glia and an increased expression of progenitor markers such as vimentin and fatty acid binding protein 7 (FABP7). In control mice, GFAP expression and astrocyte density were also significantly higher in the WT group, whereas the number of vimentin and FABP7-positive radial glia was significantly higher in the RGC-32 KO group. In vitro studies on cultured neonatal astrocytes from WT and RGC-32 KO mice showed that RGC-32 regulates a complex array of molecular networks pertaining to signal transduction, growth factor expression and secretion, and extracellular matrix (ECM) remodeling. Among the most differentially expressed factors were insulin-like growth factor 1 (IGF1), insulin-like growth factor binding proteins (IGFBPs), and connective tissue growth factor (CTGF); their expression was downregulated in RGC-32-depleted astrocytes. The nuclear translocation of STAT3, a transcription factor critical for astrogliogenesis and driving glial scar formation, was also impaired after RGC-32 silencing. Taken together, these data suggest that RGC-32 is an important regulator of astrocyte differentiation during EAE and that in the absence of RGC-32, astrocytes are unable to fully mature and become reactive astrocytes.
Copyright © 2021 Tatomir, Beltrand, Nguyen, Boodhoo, Mekala, Cudrici, Badea, Muresanu, Rus and Rus.

Entities:  

Keywords:  FABP7; GFAP; Response Gene to Complement-32; astrocyte; experimental autoimmune encephalomyelitis; radial glia; vimentin

Year:  2021        PMID: 33569054      PMCID: PMC7868332          DOI: 10.3389/fimmu.2020.608294

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  59 in total

1.  Vimentin is secreted by activated macrophages.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; David M Markovitz
Journal:  Nat Cell Biol       Date:  2003-01       Impact factor: 28.824

Review 2.  Diversity of astrocyte functions and phenotypes in neural circuits.

Authors:  Baljit S Khakh; Michael V Sofroniew
Journal:  Nat Neurosci       Date:  2015-07       Impact factor: 24.884

Review 3.  IGF-binding proteins.

Authors:  L A Bach
Journal:  J Mol Endocrinol       Date:  2017-12-18       Impact factor: 5.098

Review 4.  Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions.

Authors:  Satoshi Kubota; Masaharu Takigawa
Journal:  Clin Sci (Lond)       Date:  2015-02       Impact factor: 6.124

Review 5.  The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Roberta Brambilla
Journal:  Acta Neuropathol       Date:  2019-03-07       Impact factor: 17.088

6.  Insulin-like growth factor binding proteins: regulation in chronic active plaques in multiple sclerosis and functional analysis of glial cells.

Authors:  Daniel Chesik; Jacques De Keyser; Lisa Glazenburg; Nadine Wilczak
Journal:  Eur J Neurosci       Date:  2006-09       Impact factor: 3.386

Review 7.  Astrocytes in multiple sclerosis.

Authors:  Samuel K Ludwin; Vijayaraghava Ts Rao; Craig S Moore; Jack P Antel
Journal:  Mult Scler       Date:  2016-04-19       Impact factor: 6.312

8.  Dual role of Response gene to complement-32 in multiple sclerosis.

Authors:  Cosmin A Tegla; Cornelia D Cudrici; Philippe Azimzadeh; Anil K Singh; Richard Trippe; Ali Khan; Hegang Chen; Maria Andrian-Albescu; Walter Royal; Christopher Bever; Violeta Rus; Horea Rus
Journal:  Exp Mol Pathol       Date:  2012-09-19       Impact factor: 3.362

9.  Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers.

Authors:  Jason Pitt; Kyle C Wilcox; Vanessa Tortelli; Luan Pereira Diniz; Maira S Oliveira; Cassandra Dobbins; Xiao-Wen Yu; Sathwik Nandamuri; Flávia C A Gomes; Nadia DiNunno; Kirsten L Viola; Fernanda G De Felice; Sergio T Ferreira; William L Klein
Journal:  Mol Biol Cell       Date:  2017-08-09       Impact factor: 4.138

Review 10.  Perspectives for Ezrin and Radixin in Astrocytes: Kinases, Functions and Pathology.

Authors:  Amin Derouiche; Kathrin D Geiger
Journal:  Int J Mol Sci       Date:  2019-08-02       Impact factor: 5.923

View more
  3 in total

Review 1.  TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications.

Authors:  Jian Luo
Journal:  Biomedicines       Date:  2022-05-23

2.  RGC-32 Acts as a Hub to Regulate the Transcriptomic Changes Associated With Astrocyte Development and Reactive Astrocytosis.

Authors:  Alexandru Tatomir; Austin Beltrand; Vinh Nguyen; Jean-Paul Courneya; Dallas Boodhoo; Cornelia Cudrici; Dafin F Muresanu; Violeta Rus; Tudor C Badea; Horea Rus
Journal:  Front Immunol       Date:  2021-07-29       Impact factor: 7.561

Review 3.  Role of RGC-32 in multiple sclerosis and neuroinflammation - few answers and many questions.

Authors:  Alexandru Tatomir; Jacob Cuevas; Tudor C Badea; Dafin F Muresanu; Violeta Rus; Horea Rus
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.